RELMADA THERAPEUTICS, INC.
Business
Relmada Therapeutics is a clinical-stage biotechnology company developing novel pharmaceutical candidates for cancer and neurological disorders. Its lead product NDV-01 is a controlled-release intravesical formulation of gemcitabine and docetaxel in Phase 2 trials for non-muscle-invasive bladder cancer, with planned Phase 3 initiation in mid-2026. Sepranolone, a neurosteroid acquired in February 2025, is in Phase 2b development for Prader-Willi syndrome, Tourette syndrome, and essential tremor. The company has no approved products, generates no revenue, and relies on clinical trial progression and regulatory approvals for future commercialization.
Summary from 10-K filed 2026-03-19
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 27 | 46 | 55 | 113 | 91 | |
| General and administrative | 32 | 38 | 49 | 48 | 35 | |
| Total operating expenses | 59 | 84 | 104 | 161 | 126 | |
| Loss from operations | −59 | −84 | −104 | −161 | −126 | |
| Interest/investment income, net | 1 | 4 | 5 | — | — | |
| Realized (loss) gain on short-term investments | −79,207 | 374,926 | −4 | −585,522 | −636,012 | |
| Unrealized gain on short-term investments | 398,255 | 6,735 | 4 | −4 | −611,382 | |
| Total other income (expenses), net | 2 | 4 | 5 | 4 | −48,317 | |
| Net loss | −57 | −80 | −99 | −157 | −126 | |
| Loss per common share basic (in Dollars per share) | −1.45 | −2.65 | −3.28 | −5.3 | −7.16 | |
| Loss per common share diluted (in Dollars per share) | −1.45 | −2.65 | −3.28 | −5.3 | −7.16 | |
| Weighted average number of common shares outstanding basic (in Shares) | 39 | 30 | 30 | 30 | 18 | |
| Weighted average number of common shares outstanding diluted (in Shares) | 39 | 30 | 30 | 30 | 18 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3 | 4 | 4 | 5 | 44 | |
| Short-term investments | 90 | 41 | 92 | 143 | 167 | |
| Prepaid expenses | 977,721 | 886,461 | 1 | 4 | 11 | |
| Total current assets | 94 | 46 | 98 | 153 | 223 | |
| Other assets | 19,500 | 21,975 | 43,125 | 34,875 | 28,293 | |
| Total assets | 94 | 46 | 98 | 153 | 223 | |
| Accounts payable | 2 | 4 | 4 | 5 | 11 | |
| Accrued expenses | 5 | 6 | 9 | 7 | 4 | |
| Total current liabilities | 6 | 10 | 12 | 12 | 15 | |
| Stock appreciation rights | 1 | 4,467 | — | — | — | |
| Total liabilities | 7 | 10 | 12 | 12 | 15 | |
| Commitments and Contingencies (Note 10) | — | — | — | — | — | |
| Preferred stock value | — | — | — | — | — | |
| Common stock, $0.001 par value, 150,000,000 shares authorized, 73,333,622 and 30,174,202 shares issued and outstanding, respectively | 73,333 | 30,174 | 30,099 | 30,099 | 27,740 | |
| Additional paid-in capital | 785 | 676 | 646 | 603 | 513 | |
| Accumulated deficit | −698 | −641 | −561 | −462 | −305 | |
| Total stockholders equity | 87 | 36 | 85 | 140 | 208 | |
| Total liabilities and stockholders equity | 94 | 46 | 98 | 153 | 223 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 14 | 30 | 44 | 44 | 40 | |
| Stock appreciation rights compensation | 1 | 4,467 | — | — | — | |
| Issuance of restricted common stock | 905,226 | — | — | — | — | |
| Prepaid expenses and other assets | −88,785 | 319,746 | 3 | 7 | — | |
| Accounts payable | −3 | 624,554 | −2 | 421,040 | 3 | |
| Accrued expenses | −1 | −3 | 1 | 3 | −388,560 | |
| Net cash used in operating activities | −46 | −52 | −52 | −104 | −92 | |
| Purchase of short-term investments | −84 | −12 | −90 | −47 | — | |
| Sale of short-term investments | 36 | 64 | 141 | 67 | 169 | |
| Net cash (used in)/provided by investing activities | −48 | 52 | 50 | 20 | −54 | |
| Proceeds from issuance of common stock, net | 94 | — | — | 43 | 185 | |
| Payment of ATM fees | −73,021 | −287,088 | −98,463 | — | — | |
| Proceeds from options exercised for common stock | — | 246,747 | — | 703,720 | 668,431 | |
| Net cash provided by/(used in) financing activities | 94 | −40,341 | −98,463 | 45 | 188 | |
| Net decrease in cash and cash equivalents | −360,486 | −234,542 | −1 | −39 | 42 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is RELMADA THERAPEUTICS, INC.'s CIK number?
RELMADA THERAPEUTICS, INC.'s SEC CIK number is 0001553643 (1553643). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find RELMADA THERAPEUTICS, INC.'s SEC filings?
All of RELMADA THERAPEUTICS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did RELMADA THERAPEUTICS, INC. last report earnings?
RELMADA THERAPEUTICS, INC. (RLMD) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-055164). This is RELMADA THERAPEUTICS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is RELMADA THERAPEUTICS, INC.'s most recent earnings 8-K?
RELMADA THERAPEUTICS, INC.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001213900-26-055164. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View RELMADA THERAPEUTICS, INC.'s latest earnings 8-K →
Look up any company's CIK number →